Podcasts about employ

In today's episode of Talk Heathen, Katy Montgomerie and Secular Rarity will sort through callers as Katy drops us some fun lichen facts. First caller is D in DC who is wondering about the distinction between religion, deism, and theism when it comes to ecological circumstances. There could be a cultural practice linked with religion such as vegetarianism that can help. Having a ritualistic set of practices can have its benefits, but what happens if people decide to stop doing these things? Will ecologically beneficial religious practices be harmful in 1,000 years? Employ critical thinking to help guide that process. Next is Thomas in Canada who states that not having a belief in Jesus leads to murder. Do Christians murder and if so, were they just not real Christians? If we start throwing rules down on what makes an actual Christian, how many Christians will we have left? How does not knowing if you are going to heaven or hell have anything to do with your current state of belief? If someone isn't a Christian if they sin, and everyone sins, does that mean that no one is a Christian? This is a textbook No True Scotsman fallacy.Patrick in FL is curious about what Dawkins means by Pantheism being sexed-up atheism. When someone describes god as literally everything, it can be agreed that everything exists but to call it god is just a word game. With this definition, at the end of the day, god is indistinguishable from reality. How have you demonstrated to yourself that the universe is conscious? Even if you have, we would just have one new fact.Jasmine in Canada has some thoughts about atheists perceiving other atheists negatively. Some atheists will carry their arrogance to other domains just because they might be right about some things. Atheists can appear to be the only one that has a problem with something when in the minority, and there are also atheists that are just dickheads. Just being an atheist can put you in a position where you can't really live, while not affecting Christians. It does not matter what the label is and there is no sense in being worried where you land. It is okay to be apathetic and not care about what you call yourself. Tom in MI says that as a critical thinker, he uses Greek history as proof of the existence of gods. What is your definition of existing? Where does your god sit on this definition? What is the correspondence of ancient beliefs and the world we live in now? If people in the past thought something was real, does that make it real? We remain unconvinced of Zeus and Poseidon. Thank you for tuning into today's show, remember to thank the essential workers and turn us on next time for more of Katy's facts!

Hashtag Tendances, 29 septembre 2022 — Les livres de Reshma Saujani bannis, l'intelligence artificielle bannie de Getty Images, le PDG de Google s'adresse aux employés et l'intelligence artificielle au secours du quantique.

Bonjour à tous et bienvenue dans le ZD Tech, le podcast quotidien de la rédaction de ZDNet. Je m'appelle Clarisse Treilles, et aujourd'hui je vous explique en quoi le phénomène du “quiet quitting” redessine les frontières de notre vie professionnelle et personnelle. Vous avez peut-être entendu parler du “quiet quitting”, ou “désengagement silencieux” dans la langue de Molière, un phénomène qui émerge dans le monde du travail post-pandémique. Cette expression est apparue il y a quelques semaines sur le réseau social TikTok mais elle a fait beaucoup parler d'elle. Ce qui prouve que ce concept est loin d'être anecdotique.  Revenons d'abord à sa définition. Dans quiet quitting, il y a le terme démission (ou quitting). Mais soyons clairs, dans les faits, les employés concernés ne quittent pas vraiment leur travail. Ils effectuent les tâches qui leur sont assignées, mais ne vont cependant pas chercher à en faire “plus”.  Respecter les horaires de travail, ne plus répondre aux mails le week-end et être de façon générale moins engagé dans la vie de l'entreprise, voilà en résumé le tableau.  Autrement dit, le quiet quitting est très différent d'un abandon de poste. Les travailleurs qui s'y adonnent n'échappent pas à leur responsabilité professionnelle, mais abandonnent l'idée de se surpasser au travail. Finalement, c'est une manière aussi de dire que l'engagement au travail n'est pas le reflet de notre valeur personnelle.  Et pour les “quiet quitters”, c'est important de le souligner. Les employés qui se sentent moins engagés dans leur travail réagissent ni plus ni moins aux pressions ressenties, ainsi qu'à l'insécurité de l'emploi dans certains secteurs. Au fond, cela fait réfléchir à ce qui peut être vécu parfois comme du surmenage professionnel. Car si le haut débit, les logiciels et les appareils mobiles nous ont rendus plus productifs et plus efficaces en tant que travailleurs, peu de ces innovations ont considérablement allégé notre charge de travail. Maintenant, les managers sont-ils disposés à l'entendre de cette oreille ? Car c'est à eux aussi que revient la responsabilité de créer un meilleur environnement de travail. Et ce par le biais de la meilleure des armes en société : la communication.  Et voilà, normalement on a fait le tour du sujet. Pour en savoir plus, rendez-vous sur notre site internet. Et retrouvez tous les jours un nouvel épisode du ZDTech sur vos plateformes de podcast préférées.

After 19 years of employment for Global Affairs Canada, Wilma Ty-Cañadilla has kindly volunteered to take over a GAC Files podcast to share the reality of being a locally engaged staff member working for the Embassy to the Philippines, in Manila. A designated migration officer, Wilma has many great stories. Her job allows her to make a difference in the lives of applicants who seek to come to Canada for better education and employment opportunities and or to be reunited with family and loved ones. Emmanuelle Tremblay, Team Lead and contact person for locally engaged staff members at Global Affairs Canada, talks with Wilma Ty-Cañadilla in Manila, Philippines. | Après 19 ans à l'emploi d'Affaires mondiales Canada, Wilma Ty-Cañadilla s'est gentiment portée volontaire pour participer à un balado Dossiers d'AMC afin de nous informer de la réalité d'un employé recruté sur place travaillant pour l'ambassade à Manille, aux Philippines. En tant qu'agente de migration désignée, Wilma a beaucoup d'histoires intéressantes à raconter. Son travail lui permet de contribuer positivement à la vie des candidats à l'immigration qui cherchent à venir au Canada en quête d'une meilleure éducation et de perspectives d'emploi plus favorables, ou qui souhaitent retrouver leur famille et leurs proches. Emmanuelle Tremblay, chef d'équipe et personne-ressource pour les employés recrutés sur place à Affaires mondiales Canada, s'entretient avec Wilma Ty-Cañadilla à Manille, aux Philippines.

www.thedisabilitychannel.ca TDC Facebook - https://www.facebook.com/TheDisabilit... TDC Twitter - twitter.com/TDChannel1 Become a Patreon Supporter! -https://www.patreon.com/TheDisability... TDC Instagram - https://www.instagram.com/thedisabili... #showcasingAbilities #disabilitiesAwareness #theDisabilityChannel #showcasingAbilities #disabilitiesAwareness #theDisabilityChannel --- This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app

L'industrie alimentaire est une des catégories qui devient les plus populaires sur le podcast par les temps qui courent. Après Madame Labriski la semaine dernière et les aliments olymel le mois dernier, c'est au tour de Stéphanie Poitras, directrice général des aliments Asta de nous faire le plaisir d'être avec nous. Stéphanie, qui dirige une organisation de près de 500 employés, nous partage aujourd'hui comment l'organisation que son père a créée s'est fondée en 1982 avant qu'elle se joigne à l'aventure dès son plus jeune âge. En plus de croissance, on parle également de mentorat lors du 165e épisode. On apprend d'ailleurs qu'elle et son frère ont rapidement eu de l'accompagnement dans leur carrières en affaires afin d'accélérer leur connaissance sur le marché. Sans plus attendre, ma discussion avec Stéphanie Poitras. Pour en savoir plus sur Aliments Asta : https://alimentsasta.com/ Pour avoir un deuxième avis sur vos campagnes publicitaires : j7media.com/hypercroissance Pour discuter avec moi sur Linkedin : https://www.linkedin.com/in/antoine-gagn%C3%A9-69a94366/ Notre podcast Social Selling : https://www.j7media.com/fr/social-selling Notre podcast Commerce Élite : https://www.purecommerce.co/fr/podcast-commerce-elite Suivez-nous sur les médias sociaux : Linkedin : https://www.linkedin.com/company/podcast-d-hypercroissance/ Facebook : https://www.facebook.com/podcastHypercroissance Instagram : https://www.instagram.com/podcasthypercroissance/

Chaque soir, Olivier Delacroix vous ouvre la Libre antenne. Pas de jugements ni de tabous, une conversation franche mais aussi des réponses aux questions que les auditeurs se posent. Un moment d'échange et de partage propice à la confidence pour repartir le cœur plus léger.

On today's episode, Dennis talks with Army Ranger and Strength & Conditioning Coach, Matt Hibler. Matt was a law enforcement officer for 4 years before he decided to join the Military and become an Army Ranger at 28 years old. Matt began writing lay outs and programs on strength and conditioning for LEO and Military candidates to implement and prepare them for academies and boot camps. Matt discusses structuring your training to meet your goals, how to commit and employ discipline for maximum success in fitness. Read Matt's full program here: longtermtraining.substack.com If you like what you are hearing and want to stay in the loop with the latest in Street Cop Training, please follow our Facebook Page: https://www.facebook.com/StreetCopTraining Don't forget to subscribe and rate the podcast, it truly helps!

Chaque soir, Olivier Delacroix vous ouvre la Libre antenne. Pas de jugements ni de tabous, une conversation franche mais aussi des réponses aux questions que les auditeurs se posent. Un moment d'échange et de partage propice à la confidence pour repartir le cœur plus léger.

With the news that An Bord Pleanála has granted planning permission for a new film studio complex here in Co Wexford which could eventually employ up to 30 people we spoke to one of the backers of the project film financier John Gleeson and Senator Malcolm Byrne

Your Friendly Neighborhood Bearded Weirded Nolan Bryan, The One The Only Pastor Gary Podosek and The Man Behind the Helm Steve Cattel, throw the gauntlet down. The time to vote with the Bible, your convictions and your wallet are now! Will you have the courage to stand up and fight or will you cower in fear and shamefully be the reason it all gets worsehttps://linktr.ee/Church_and_State - to get to all our links and info!If you like what you see and would like to donate to help us grow then please follow our Patreon @ https://www.patreon.com/Church_And_Statehttps://www.patreon.com/Church_And_StateMusic created by Tom MacDonald - Thank you sir for the permission to use it!

Claudette Houle, coordonnatrice des ressources humaines du Collège Champlain de Saint-Lambert, présente les postes à combler et les avantages de rejoindre leur équipe. Cégep anglophone situé à quelques pas du Terminus Longueuil Établie depuis 1972 donc maintenant 50 ans. Leur vision : Offrir des programmes et des services exceptionnel, novateurs et de haut calibre, former des diplômés reconnus pour l'excellence de leurs connaissances et leurs compétences, attirer et retenir un personnel enseignant et non enseignant hautement qualifié, être un collège favorisant l'apprentissage. Gilles Robillard et Jimmy Carrière tous deux agents de développement chez Alliance carrière travail nous présente les services aux entreprises. Nous sommes les experts en employabilité pour combler les besoins de main-d'œuvre des entreprises et optimiser votre processus de recrutement ! Notre équipe rencontre 3 500 chercheurs d'emploi par année aux profils variés et ayant chacun un objectif d'emploi qui lui est propre. À travers nos trois centres de services, nous accompagnons autant les jeunes travailleurs à la recherche d'un premier emploi que les candidats d'expérience internationale ou les travailleurs expérimentés en transition professionnelle. Liens et ressources de l'épisode : https://www.champlainonline.com/  https://alliancect.ca/   Claudine Lepage, Animatrice Direction Emploi : c.lepage@alliancect.ca  Podcast : https://www.fm1033.ca/podcast_fm1033/direction-emploi/ 

Businesses across Iowa can get all kinds of workforce help through our IowaWORKS offices. We're highlighting these employer resources with Chris Kula, IowaWORKS Business Engagement Consultant, who shares how he and several of his colleagues work personally with business leaders to achieve their hiring goals. Listen in to find out how business engagement consultants can make a difference in your company today! 

With prospects & polling trending upwards for Republicans in tight races across the country, Charlie looks a level deeper and lays out a prescriptive warning against Democrats' scheming ways. He walks through 5 distinct impediments to a Republican Landslide victory in the November Midterms, surgically laying out the likelihood of each, and shares how we can be prepared to blunt each of their attacks why it remains more important than ever, in the face of their meddling, to stay vigilant and peaceful as a movement. Support the show: http://www.charliekirk.com/supportSee omnystudio.com/listener for privacy information.

Go online to PeerView.com/GZM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in overactive bladder discusses strategies and criteria for OAB screening and diagnosis, as well as current and emerging treatment options. A patient interview highlights the burden of disease and a 3D video illustrates the mechanisms of action of various treatments. Upon completion of this activity, participants should be better able to: Develop a strategy to implement OAB screening into clinical practice; Employ recommended diagnostic criteria to differentiate OAB from other urinary conditions with shared symptomology; and Implement individually appropriate OAB treatment plans that minimize risks related to cardiovascular health, dementia, and polypharmacy concerns.

Go online to PeerView.com/GZM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in overactive bladder discusses strategies and criteria for OAB screening and diagnosis, as well as current and emerging treatment options. A patient interview highlights the burden of disease and a 3D video illustrates the mechanisms of action of various treatments. Upon completion of this activity, participants should be better able to: Develop a strategy to implement OAB screening into clinical practice; Employ recommended diagnostic criteria to differentiate OAB from other urinary conditions with shared symptomology; and Implement individually appropriate OAB treatment plans that minimize risks related to cardiovascular health, dementia, and polypharmacy concerns.

Go online to PeerView.com/GZM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in overactive bladder discusses strategies and criteria for OAB screening and diagnosis, as well as current and emerging treatment options. A patient interview highlights the burden of disease and a 3D video illustrates the mechanisms of action of various treatments. Upon completion of this activity, participants should be better able to: Develop a strategy to implement OAB screening into clinical practice; Employ recommended diagnostic criteria to differentiate OAB from other urinary conditions with shared symptomology; and Implement individually appropriate OAB treatment plans that minimize risks related to cardiovascular health, dementia, and polypharmacy concerns.

Go online to PeerView.com/GZM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in overactive bladder discusses strategies and criteria for OAB screening and diagnosis, as well as current and emerging treatment options. A patient interview highlights the burden of disease and a 3D video illustrates the mechanisms of action of various treatments. Upon completion of this activity, participants should be better able to: Develop a strategy to implement OAB screening into clinical practice; Employ recommended diagnostic criteria to differentiate OAB from other urinary conditions with shared symptomology; and Implement individually appropriate OAB treatment plans that minimize risks related to cardiovascular health, dementia, and polypharmacy concerns.

Go online to PeerView.com/GZM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in overactive bladder discusses strategies and criteria for OAB screening and diagnosis, as well as current and emerging treatment options. A patient interview highlights the burden of disease and a 3D video illustrates the mechanisms of action of various treatments. Upon completion of this activity, participants should be better able to: Develop a strategy to implement OAB screening into clinical practice; Employ recommended diagnostic criteria to differentiate OAB from other urinary conditions with shared symptomology; and Implement individually appropriate OAB treatment plans that minimize risks related to cardiovascular health, dementia, and polypharmacy concerns.

Go online to PeerView.com/GZM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in overactive bladder discusses strategies and criteria for OAB screening and diagnosis, as well as current and emerging treatment options. A patient interview highlights the burden of disease and a 3D video illustrates the mechanisms of action of various treatments. Upon completion of this activity, participants should be better able to: Develop a strategy to implement OAB screening into clinical practice; Employ recommended diagnostic criteria to differentiate OAB from other urinary conditions with shared symptomology; and Implement individually appropriate OAB treatment plans that minimize risks related to cardiovascular health, dementia, and polypharmacy concerns.

Go online to PeerView.com/GZM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in overactive bladder discusses strategies and criteria for OAB screening and diagnosis, as well as current and emerging treatment options. A patient interview highlights the burden of disease and a 3D video illustrates the mechanisms of action of various treatments. Upon completion of this activity, participants should be better able to: Develop a strategy to implement OAB screening into clinical practice; Employ recommended diagnostic criteria to differentiate OAB from other urinary conditions with shared symptomology; and Implement individually appropriate OAB treatment plans that minimize risks related to cardiovascular health, dementia, and polypharmacy concerns.

Go online to PeerView.com/GZM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in overactive bladder discusses strategies and criteria for OAB screening and diagnosis, as well as current and emerging treatment options. A patient interview highlights the burden of disease and a 3D video illustrates the mechanisms of action of various treatments. Upon completion of this activity, participants should be better able to: Develop a strategy to implement OAB screening into clinical practice; Employ recommended diagnostic criteria to differentiate OAB from other urinary conditions with shared symptomology; and Implement individually appropriate OAB treatment plans that minimize risks related to cardiovascular health, dementia, and polypharmacy concerns.

In this episode, Jeannette talks to Amanda Matthews who is something of a travel icon. She started working in the industry as a teenager and went on to climb the corporate ladder at Co-Op Travelcare, where she became the MD. Until she started her own company Designer Travel, which today, employs 105 home-based travel experts and a large support team. They provide high-quality yet affordable luxury holidays.   Amanda explains how she used her passion to drive her success and her thirst for knowledge to enable her to excel in every role she took on. A way of working that took her to the top quickly at a time when very, very few women were offered senior roles. As well as sharing how she set up her business, ran it through Co-Vid, managed being a working mum and being treated for cancer.   KEY TAKEAWAYS   When you leave a big corporate job, you will find out who your faithful friends are. Employ people who have the same values as you. Going the extra mile will always create repeat customers. Your outlook on life affects everything. There are 2 ways to look at everything, always choose to look at things positively. Everyone has bad days. Learning how to get through them is key. CoVid was incredibly hard, but it made Amanda and her team stronger and enabled them to survive. Now, they are thriving. Honest communication is essential. Stay close to your team, understand them, and respond to their needs. Don´t stress about failing. Learn from it, but don´t dwell on it. If something´s wrong, own it, and face up to it right away. Whatever problem you have look at the worst-case scenario then work back from there. That prepares you to solve the problem come what may.   BEST MOMENTS ‘I´ve always run the branch, the department, the company I was leading as if it was my own business. ´ ‘If you as the leader show that you can get through tough times, people will stay on the bus with you.' ‘Always take the positive out of the negative.'   This is the perfect time to get focused on what YOU want to really achieve in your business, career, and life. It's never too late to be BRAVE and BOLD and unlock your inner BRILLIANCE. If you'd like to jump on a free mentoring session just DM Jeannette at info@jeannettelinfootassociates.com or sign up via Jeannette's linktree https://linktr.ee/JLinfoot   VALUABLE RESOURCES Brave, Bold, Brilliant podcast series - https://podcasts.apple.com/gb/podcast/brave-bold-brilliant-podcast/id1524278970   EPISODE RESOURCES Website - www.designertravel.co.uk Facebook - @designertravel Instagram - @designertravel Twitter - @designertravel and @amandamatthews1 LinkedIn - https://www.linkedin.com/company/28165197/admin/ Tik Tok - @designertravel   ABOUT THE GUEST Amanda Matthews got into travel from an early age. She gained a Travel and Tourism diploma at college whilst working a full-time job at WH Smith Travel in Coventry. Then, moved to a different travel agency that very quickly got taken over by Coop Travelcare. There she became one of the youngest managers at 18. Throughout her 21 years of service with Coop Travelcare, she worked as a regional manager, and operations director before becoming the managing director. At the time, the business had over 500 retail shops and call centres. As well as selling online.  In 2008, the two largest Co-operatives, The Co-operative Group and United Northwest merged. At this point, the travel, food, and funeral arms of the Co-Op also merged. Around that time, Amanda took a redundancy package to set up her own business, from scratch. That was when Designer Travel was born. Today, Designer Travel employs 105 home-based luxury travel experts, all of whom have travelled extensively themselves. They are supported and coordinated by the staff who work out of the company's admin centre, in Ramsbottom. The business also has a physical retail outlet, a website, and several social media channels. All of these are dedicated to creating the perfect holiday for any traveller, in any part of the world.  Recruiting the right experts and offering high levels of support has been a key driver for Designer Travel, which 100% has an amazing DREAMTEAM. Building solid relationships with clients and suppliers has led to the creation of a successful luxury travel business. Something that Designer Travel has and always will aim to be.   ABOUT THE HOST Jeannette Linfoot is a highly regarded senior executive, property investor, board advisor, and business mentor with over 25 years of global professional business experience across the travel, leisure, hospitality, and property sectors. Having bought, ran, and sold businesses all over the world, Jeannette now has a portfolio of her own businesses and also advises and mentors other business leaders to drive forward their strategies as well as their own personal development.   Jeannette is a down-to-earth leader, a passionate champion for diversity & inclusion, and a huge advocate of nurturing talent so every person can unleash their full potential and live their dreams.    CONTACT THE HOST Jeannette's linktree - https://linktr.ee/JLinfoot https://www.jeannettelinfootassociates.com/ YOUTUBE - https://www.youtube.com/channel/UCtsU57ZGoPhm55_X0qF16_Q LinkedIn - https://uk.linkedin.com/in/jeannettelinfoot Facebook - https://uk.linkedin.com/in/jeannettelinfoot Instagram - https://www.instagram.com/jeannette.linfoot/ Email - info@jeannettelinfootassociates.com   Podcast Description   Jeannette Linfoot talks to incredible people about their experiences of being Brave, Bold & Brilliant, which have allowed them to unleash their full potential in business, their careers, and life in general. From the boardroom tables of ‘big' international businesses to the dining room tables of entrepreneurial start-ups, how to overcome challenges, embrace opportunities and take risks, whilst staying ‘true' to yourself is the order of the day.business, growth, scale, marketing, investment, investing, entrepreneurship, coach, consultant, mindset, six figures, seven figures, travel, industry, ROI, B2B, inspirational: https://linktr.ee/JLinfootSee omnystudio.com/listener for privacy information.

Du lundi au vendredi dans Demain au travail, un responsable d'entreprise raconte au micro d'Europe 1 une innovation mise en place au sein de son entreprise pour le bien-être de ses salariés.

Cours Halakha Time du Jeudi 8 Septembre 2022 (durée : 6 minutes) donné par Rav Reouven COHEN.

Tous les jours à 5h50, Anthony Morel, expert High-Tech vous fait découvrir les dernières actus techno, dans Charles Matin, sur RMC. De l'info, de l'humour et de la bonne humeur… Cette année, Charles Magnien gagne une demi-heure. Avec Anaïs Castagna, ils accompagnent jusqu'à 6h30 les Français qui se lèvent tôt. Nouveautés cette saison : Arthur Asquin rejoint l'équipe de Charles Matin avec une nouvelle chronique : l'info marquante du jour à ne pas manquer ; et pour ne rien louper de l'actualité sportive, Thibaud Texeire incarnera tous les matins la Story Sport. RMC est une radio généraliste, essentiellement axée sur l'actualité et sur l'interactivité avec les auditeurs, dans un format 100% parlé, inédit en France. La grille des programmes de RMC s'articule autour de rendez-vous phares comme Apolline Matin (6h30-8h30), les Grandes Gueules (9h-12h), Estelle Midi (12h-15h), Super Moscato Show (15h-18h), Rothen s'enflamme (18h-20h), l'After Foot (20h-minuit).

Payer en retard son employé ou prestataire

Go online to PeerView.com/QER860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The current standards of care for managing food allergies require strict avoidance measures and prompt treatment of allergic reactions with emergency medications. However, oral immunotherapies and biologic agents are currently in development for the treatment of IgE-mediated food allergies, replacing the need for oral food challenges. Our expert faculty will share strategies for optimal clinical decision-making for patients with food allergy that is based on the latest evidence, best practice recommendations, and effective multidisciplinary collaboration. Upon completion of this activity, participants should be better able to: Describe the pathophysiology of IgE-mediated food allergy and how these insights into underlying mechanisms can translate to the use of biomarkers to allow more personalized treatment for patients; Apply strategies to differentially diagnose patients with IgE-mediated food allergies using the latest criteria and expert recommendations; Identify patients with IgE-mediated food allergies who might be eligible for novel and emerging treatments and/or enrollment in clinical trials based on the latest evidence on efficacy and safety; and Employ a multidisciplinary approach to the treatment of patients with food allergy to optimize care and improve quality of life.

Go online to PeerView.com/QER860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The current standards of care for managing food allergies require strict avoidance measures and prompt treatment of allergic reactions with emergency medications. However, oral immunotherapies and biologic agents are currently in development for the treatment of IgE-mediated food allergies, replacing the need for oral food challenges. Our expert faculty will share strategies for optimal clinical decision-making for patients with food allergy that is based on the latest evidence, best practice recommendations, and effective multidisciplinary collaboration. Upon completion of this activity, participants should be better able to: Describe the pathophysiology of IgE-mediated food allergy and how these insights into underlying mechanisms can translate to the use of biomarkers to allow more personalized treatment for patients; Apply strategies to differentially diagnose patients with IgE-mediated food allergies using the latest criteria and expert recommendations; Identify patients with IgE-mediated food allergies who might be eligible for novel and emerging treatments and/or enrollment in clinical trials based on the latest evidence on efficacy and safety; and Employ a multidisciplinary approach to the treatment of patients with food allergy to optimize care and improve quality of life.

Go online to PeerView.com/RXV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In PeerView's latest inExchange learning opportunity, experts from a gynecologic cancer center of excellence share the latest in modern, molecularly informed, and equitable therapy for EC using a team-based approach. They will share the rationale, science, and evidence behind novel therapies for recurrent and advanced EC, practical strategies to put these data into practice to develop individualized treatment plans, and interprofessional strategies supporting the safe and appropriate use of ICIs in community settings. Concluding with their perspectives on the future of treatment for recurrent and advanced EC—including the importance of diversifying clinical trial enrollment—this presentation is a quick, informative, and engaging chance to expand your knowledge and benefit your patients with EC. Upon completion of this activity, participants should be better able to: Describe the rationales, therapeutic roles, and key efficacy/safety evidence on novel and emerging therapies, including immuno-oncology treatments and innovative maintenance therapies, for subsets of patients with recurrent or advanced EC; Develop contemporary, personalized management plans for patients with recurrent or advanced EC that incorporate new evidence and guideline recommendations, individual clinical and molecular features (eg, MMR/MSI phenotype), and patient goals and preferences; and Employ proactive, interprofessional team-based strategies to address practical aspects of novel therapies for recurrent or advanced EC, including adverse event management, patient education, and disparities in clinical care and research.

Go online to PeerView.com/QER860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The current standards of care for managing food allergies require strict avoidance measures and prompt treatment of allergic reactions with emergency medications. However, oral immunotherapies and biologic agents are currently in development for the treatment of IgE-mediated food allergies, replacing the need for oral food challenges. Our expert faculty will share strategies for optimal clinical decision-making for patients with food allergy that is based on the latest evidence, best practice recommendations, and effective multidisciplinary collaboration. Upon completion of this activity, participants should be better able to: Describe the pathophysiology of IgE-mediated food allergy and how these insights into underlying mechanisms can translate to the use of biomarkers to allow more personalized treatment for patients; Apply strategies to differentially diagnose patients with IgE-mediated food allergies using the latest criteria and expert recommendations; Identify patients with IgE-mediated food allergies who might be eligible for novel and emerging treatments and/or enrollment in clinical trials based on the latest evidence on efficacy and safety; and Employ a multidisciplinary approach to the treatment of patients with food allergy to optimize care and improve quality of life.

Un scandale qui a bien failli être passé sous silence au Royaume-Uni. L'histoire des postiers accusés à tort d'avoir volé de l'argent dans la caisse. La pire erreur de l'histoire judiciaire britannique récente. Des vies ruinées, certains ont connu la prison. Une affaire qui a mis 20 ans à être entièrement dévoilée. 736 femmes et hommes condamnés pour rien. Ils attendent encore des réparations. Voici leur histoire.  (Rediffusion du 12 mai 2022)

Go online to PeerView.com/QER860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The current standards of care for managing food allergies require strict avoidance measures and prompt treatment of allergic reactions with emergency medications. However, oral immunotherapies and biologic agents are currently in development for the treatment of IgE-mediated food allergies, replacing the need for oral food challenges. Our expert faculty will share strategies for optimal clinical decision-making for patients with food allergy that is based on the latest evidence, best practice recommendations, and effective multidisciplinary collaboration. Upon completion of this activity, participants should be better able to: Describe the pathophysiology of IgE-mediated food allergy and how these insights into underlying mechanisms can translate to the use of biomarkers to allow more personalized treatment for patients; Apply strategies to differentially diagnose patients with IgE-mediated food allergies using the latest criteria and expert recommendations; Identify patients with IgE-mediated food allergies who might be eligible for novel and emerging treatments and/or enrollment in clinical trials based on the latest evidence on efficacy and safety; and Employ a multidisciplinary approach to the treatment of patients with food allergy to optimize care and improve quality of life.

Go online to PeerView.com/QER860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The current standards of care for managing food allergies require strict avoidance measures and prompt treatment of allergic reactions with emergency medications. However, oral immunotherapies and biologic agents are currently in development for the treatment of IgE-mediated food allergies, replacing the need for oral food challenges. Our expert faculty will share strategies for optimal clinical decision-making for patients with food allergy that is based on the latest evidence, best practice recommendations, and effective multidisciplinary collaboration. Upon completion of this activity, participants should be better able to: Describe the pathophysiology of IgE-mediated food allergy and how these insights into underlying mechanisms can translate to the use of biomarkers to allow more personalized treatment for patients; Apply strategies to differentially diagnose patients with IgE-mediated food allergies using the latest criteria and expert recommendations; Identify patients with IgE-mediated food allergies who might be eligible for novel and emerging treatments and/or enrollment in clinical trials based on the latest evidence on efficacy and safety; and Employ a multidisciplinary approach to the treatment of patients with food allergy to optimize care and improve quality of life.

Go online to PeerView.com/RXV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In PeerView's latest inExchange learning opportunity, experts from a gynecologic cancer center of excellence share the latest in modern, molecularly informed, and equitable therapy for EC using a team-based approach. They will share the rationale, science, and evidence behind novel therapies for recurrent and advanced EC, practical strategies to put these data into practice to develop individualized treatment plans, and interprofessional strategies supporting the safe and appropriate use of ICIs in community settings. Concluding with their perspectives on the future of treatment for recurrent and advanced EC—including the importance of diversifying clinical trial enrollment—this presentation is a quick, informative, and engaging chance to expand your knowledge and benefit your patients with EC. Upon completion of this activity, participants should be better able to: Describe the rationales, therapeutic roles, and key efficacy/safety evidence on novel and emerging therapies, including immuno-oncology treatments and innovative maintenance therapies, for subsets of patients with recurrent or advanced EC; Develop contemporary, personalized management plans for patients with recurrent or advanced EC that incorporate new evidence and guideline recommendations, individual clinical and molecular features (eg, MMR/MSI phenotype), and patient goals and preferences; and Employ proactive, interprofessional team-based strategies to address practical aspects of novel therapies for recurrent or advanced EC, including adverse event management, patient education, and disparities in clinical care and research.

Go online to PeerView.com/RXV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In PeerView's latest inExchange learning opportunity, experts from a gynecologic cancer center of excellence share the latest in modern, molecularly informed, and equitable therapy for EC using a team-based approach. They will share the rationale, science, and evidence behind novel therapies for recurrent and advanced EC, practical strategies to put these data into practice to develop individualized treatment plans, and interprofessional strategies supporting the safe and appropriate use of ICIs in community settings. Concluding with their perspectives on the future of treatment for recurrent and advanced EC—including the importance of diversifying clinical trial enrollment—this presentation is a quick, informative, and engaging chance to expand your knowledge and benefit your patients with EC. Upon completion of this activity, participants should be better able to: Describe the rationales, therapeutic roles, and key efficacy/safety evidence on novel and emerging therapies, including immuno-oncology treatments and innovative maintenance therapies, for subsets of patients with recurrent or advanced EC; Develop contemporary, personalized management plans for patients with recurrent or advanced EC that incorporate new evidence and guideline recommendations, individual clinical and molecular features (eg, MMR/MSI phenotype), and patient goals and preferences; and Employ proactive, interprofessional team-based strategies to address practical aspects of novel therapies for recurrent or advanced EC, including adverse event management, patient education, and disparities in clinical care and research.

Go online to PeerView.com/RXV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In PeerView's latest inExchange learning opportunity, experts from a gynecologic cancer center of excellence share the latest in modern, molecularly informed, and equitable therapy for EC using a team-based approach. They will share the rationale, science, and evidence behind novel therapies for recurrent and advanced EC, practical strategies to put these data into practice to develop individualized treatment plans, and interprofessional strategies supporting the safe and appropriate use of ICIs in community settings. Concluding with their perspectives on the future of treatment for recurrent and advanced EC—including the importance of diversifying clinical trial enrollment—this presentation is a quick, informative, and engaging chance to expand your knowledge and benefit your patients with EC. Upon completion of this activity, participants should be better able to: Describe the rationales, therapeutic roles, and key efficacy/safety evidence on novel and emerging therapies, including immuno-oncology treatments and innovative maintenance therapies, for subsets of patients with recurrent or advanced EC; Develop contemporary, personalized management plans for patients with recurrent or advanced EC that incorporate new evidence and guideline recommendations, individual clinical and molecular features (eg, MMR/MSI phenotype), and patient goals and preferences; and Employ proactive, interprofessional team-based strategies to address practical aspects of novel therapies for recurrent or advanced EC, including adverse event management, patient education, and disparities in clinical care and research.

Go online to PeerView.com/RXV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In PeerView's latest inExchange learning opportunity, experts from a gynecologic cancer center of excellence share the latest in modern, molecularly informed, and equitable therapy for EC using a team-based approach. They will share the rationale, science, and evidence behind novel therapies for recurrent and advanced EC, practical strategies to put these data into practice to develop individualized treatment plans, and interprofessional strategies supporting the safe and appropriate use of ICIs in community settings. Concluding with their perspectives on the future of treatment for recurrent and advanced EC—including the importance of diversifying clinical trial enrollment—this presentation is a quick, informative, and engaging chance to expand your knowledge and benefit your patients with EC. Upon completion of this activity, participants should be better able to: Describe the rationales, therapeutic roles, and key efficacy/safety evidence on novel and emerging therapies, including immuno-oncology treatments and innovative maintenance therapies, for subsets of patients with recurrent or advanced EC; Develop contemporary, personalized management plans for patients with recurrent or advanced EC that incorporate new evidence and guideline recommendations, individual clinical and molecular features (eg, MMR/MSI phenotype), and patient goals and preferences; and Employ proactive, interprofessional team-based strategies to address practical aspects of novel therapies for recurrent or advanced EC, including adverse event management, patient education, and disparities in clinical care and research.

In this episode, Jeannette talks to Duncan O´Rourke who is the Chief Executive Officer of Northern Europe at Accor. He talks about his early life, living in South Africa, and then being educated in an English boarding school. How these things shaped the man he became and the career path he chose to follow. Duncan explains what it is like to run a brand that serves multiple sectors of the travel business. They also talk about how to build a strong team even though there is a severe shortage of talented people, at the moment. Dealing with the challenge of climbing the corporate ladder. As well as learning to switch gears and stop being the CEO when you are at home.   KEY TAKEAWAYS What luxury is and means to people is constantly changing. Personalised service is a key component of what people expect from a luxury brand. You can't manage the IBIS brand the same way you manage the Raffles Hotel brand. But attention to detail is essential at all levels of the hotel industry. Climbing the corporate ladder is stressful. For every new role, you will have holes in your knowledge. Being honest about what you don't know is important. Stress is a part of respecting the challenge that you are facing. Surround yourself with people who are better than you. Employ self-starters who have sound values. There is a massive shortage of talented staff within the travel industry. Duncan estimates between 10 and 15%. During times of crisis, clear and regular communication is vital. Diversifying your team must not be about quotas. You just need to be genuinely open to hiring the right person for the job.   BEST MOMENTS ‘For me, luxury is limited by definition, it is personalised. ´ ‘During those times when you have those sleepless nights, remind yourself what is going right.' ‘Our clients are diverse, so we embrace diversity and think it's important.' ‘Pretty good is not good enough. You always want to deliver your best.'   This is the perfect time to get focused on what YOU want to really achieve in your business, career, and life. It's never too late to be BRAVE and BOLD and unlock your inner BRILLIANCE. If you'd like to join Jeannette's FREE Business Impact Seminar just DM Jeannette at info@jeannettelinfootassociates.com or sign up via Jeannette's linktree https://linktr.ee/JLinfoot    VALUABLE RESOURCES Brave, Bold, Brilliant podcast series - https://podcasts.apple.com/gb/podcast/brave-bold-brilliant-podcast/id1524278970   EPISODE RESOURCES LinkedIn : https://ch.linkedin.com/in/duncan-o-rourke Email: duncan.orourke@accor.com   ABOUT THE GUEST Duncan O'Rourke is Chief Executive Officer Northern Europe at Accor. Duncan joined Accor in 2016 as COO for the Luxury and Premium segment before taking over as COO Central Europe. In his capacity, he was responsible for more than 470 hotels and 13 brands in Germany, Austria and Switzerland. Upon his appointment as CEO of Northern Europe in October 2020 Duncan became a member of the Group's Executive Committee. Duncan has over 30 years of experience within the industry and has held several executive positions in Europe, the US and the Middle East. From 2004, he served as General Manager for Kempinski in various destinations before being promoted to the position of Region Director overseeing the Operations of the properties in the Middle East. In 2008, he was appointed Chief Operating Officer of Kempinski Hotels and became part of the Management Board at the same time. Duncan holds a degree from Cesar Ritz Colleges in Switzerland and an MBA from Reims Management School.   ABOUT THE HOST Jeannette Linfoot is a highly regarded senior executive, property investor, board advisor, and business mentor with over 25 years of global professional business experience across the travel, leisure, hospitality, and property sectors. Having bought, ran, and sold businesses all over the world, Jeannette now has a portfolio of her own businesses and also advises and mentors other business leaders to drive forward their strategies as well as their own personal development. Jeannette is a down-to-earth leader, a passionate champion for diversity & inclusion, and a huge advocate of nurturing talent so every person can unleash their full potential and live their dreams.    CONTACT THE HOST Jeannette's linktree - https://linktr.ee/JLinfoot https://www.jeannettelinfootassociates.com/ YOUTUBE - https://www.youtube.com/channel/UCtsU57ZGoPhm55_X0qF16_Q LinkedIn - https://uk.linkedin.com/in/jeannettelinfoot Facebook - https://uk.linkedin.com/in/jeannettelinfoot Instagram - https://www.instagram.com/jeannette.linfoot/ Email - info@jeannettelinfootassociates.com   Podcast Description Jeannette Linfoot talks to incredible people about their experiences of being Brave, Bold & Brilliant, which have allowed them to unleash their full potential in business, their careers, and life in general. From the boardroom tables of ‘big' international businesses to the dining room tables of entrepreneurial start-ups, how to overcome challenges, embrace opportunities and take risks, whilst staying ‘true' to yourself is the order of the day.business, growth, scale, marketing, investment, investing, entrepreneurship, coach, consultant, mindset, six figures, seven figures, travel, industry, ROI, B2B, inspirational: https://linktr.ee/JLinfootSee omnystudio.com/listener for privacy information.

Very few habits are as destructive to human happiness as looking at what others have and do—and feeling that you're inferior.Yet in this world of social media and digital diversion, so many of us are spending the better hours of our best days looking at the lives of others and measuring our success by what we see.Employ the self-talk of superstardom and you hardwire the faith and confidence needed to believe in your mighty mission even where you are only an army of one.Stand true to your right to be great. And speak to yourself like the leader, visionary and possibilitarian you are. No one alive today thinks quite like you, feels as you do and has the same configuration of strengths and abilities that you have.If you'd like so much more information like this to keep you focused on your mission in these trying times along with science-backed insights and daily practices to increase your happiness, performance and peacefulness......Go ahead and read my latest book The Everyday Hero Manifesto. It's become a worldwide phenomenon because it works. Period.*****FOLLOW ROBIN SHARMA:InstagramFacebookTwitterYouTube

Go online to PeerView.com/WVA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in dermatology discusses team-based care and novel therapies in the treatment of pediatric patients with moderate to severe atopic dermatitis. Upon completion of this activity, participants should be better able to: Describe age-related and race-related differences in the phenotypic expression of atopic dermatitis (AD); Employ evidence-based strategies to determine disease impact and guide treatment decisions in pediatric patients with AD; Discuss the rationale for targeting type 2 cytokines as a therapeutic approach in AD; Assess clinical data on new and emerging treatment options for pediatric patients with moderate to severe AD; and Employ a team-based and patient-centered management approach to children and adolescents with atopic dermatitis to prevent flare-ups, identify comorbidities, maximize health-related quality of life, and recognize treatment-related side effects.

Go online to PeerView.com/WVA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in dermatology discusses team-based care and novel therapies in the treatment of pediatric patients with moderate to severe atopic dermatitis. Upon completion of this activity, participants should be better able to: Describe age-related and race-related differences in the phenotypic expression of atopic dermatitis (AD); Employ evidence-based strategies to determine disease impact and guide treatment decisions in pediatric patients with AD; Discuss the rationale for targeting type 2 cytokines as a therapeutic approach in AD; Assess clinical data on new and emerging treatment options for pediatric patients with moderate to severe AD; and Employ a team-based and patient-centered management approach to children and adolescents with atopic dermatitis to prevent flare-ups, identify comorbidities, maximize health-related quality of life, and recognize treatment-related side effects.

Go online to PeerView.com/WVA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in dermatology discusses team-based care and novel therapies in the treatment of pediatric patients with moderate to severe atopic dermatitis. Upon completion of this activity, participants should be better able to: Describe age-related and race-related differences in the phenotypic expression of atopic dermatitis (AD); Employ evidence-based strategies to determine disease impact and guide treatment decisions in pediatric patients with AD; Discuss the rationale for targeting type 2 cytokines as a therapeutic approach in AD; Assess clinical data on new and emerging treatment options for pediatric patients with moderate to severe AD; and Employ a team-based and patient-centered management approach to children and adolescents with atopic dermatitis to prevent flare-ups, identify comorbidities, maximize health-related quality of life, and recognize treatment-related side effects.

Go online to PeerView.com/WVA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in dermatology discusses team-based care and novel therapies in the treatment of pediatric patients with moderate to severe atopic dermatitis. Upon completion of this activity, participants should be better able to: Describe age-related and race-related differences in the phenotypic expression of atopic dermatitis (AD); Employ evidence-based strategies to determine disease impact and guide treatment decisions in pediatric patients with AD; Discuss the rationale for targeting type 2 cytokines as a therapeutic approach in AD; Assess clinical data on new and emerging treatment options for pediatric patients with moderate to severe AD; and Employ a team-based and patient-centered management approach to children and adolescents with atopic dermatitis to prevent flare-ups, identify comorbidities, maximize health-related quality of life, and recognize treatment-related side effects.

Go online to PeerView.com/MNQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a recent live webcast, two experts in NTM-LD who represent pulmonology and infectious disease will offer their perspectives to help you achieve greater insight into the recognition and diagnosis of NTM-LD. You will hear the most up-to-date evidence on the management of NTM-LD, including both pharmacologic and nonpharmacologic approaches, and you will receive strategies for handling challenges that arise during treatment. Upon completion of this activity, participants should be better able to: Employ updated ATS/IDSA guidelines to diagnose and manage NTM-LD promptly; Develop individualized treatment regimens encompassing pharmacologic and nonpharmacologic approaches for patients with NTM-LD according to guideline recommendations and patient factors/goals; and Apply team-based strategies to manage medication adverse events, improve treatment adherence, decrease disease burden, and optimize patient outcomes.

Go online to PeerView.com/MNQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a recent live webcast, two experts in NTM-LD who represent pulmonology and infectious disease will offer their perspectives to help you achieve greater insight into the recognition and diagnosis of NTM-LD. You will hear the most up-to-date evidence on the management of NTM-LD, including both pharmacologic and nonpharmacologic approaches, and you will receive strategies for handling challenges that arise during treatment. Upon completion of this activity, participants should be better able to: Employ updated ATS/IDSA guidelines to diagnose and manage NTM-LD promptly; Develop individualized treatment regimens encompassing pharmacologic and nonpharmacologic approaches for patients with NTM-LD according to guideline recommendations and patient factors/goals; and Apply team-based strategies to manage medication adverse events, improve treatment adherence, decrease disease burden, and optimize patient outcomes.

Go online to PeerView.com/MNQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a recent live webcast, two experts in NTM-LD who represent pulmonology and infectious disease will offer their perspectives to help you achieve greater insight into the recognition and diagnosis of NTM-LD. You will hear the most up-to-date evidence on the management of NTM-LD, including both pharmacologic and nonpharmacologic approaches, and you will receive strategies for handling challenges that arise during treatment. Upon completion of this activity, participants should be better able to: Employ updated ATS/IDSA guidelines to diagnose and manage NTM-LD promptly; Develop individualized treatment regimens encompassing pharmacologic and nonpharmacologic approaches for patients with NTM-LD according to guideline recommendations and patient factors/goals; and Apply team-based strategies to manage medication adverse events, improve treatment adherence, decrease disease burden, and optimize patient outcomes.

Go online to PeerView.com/MNQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a recent live webcast, two experts in NTM-LD who represent pulmonology and infectious disease will offer their perspectives to help you achieve greater insight into the recognition and diagnosis of NTM-LD. You will hear the most up-to-date evidence on the management of NTM-LD, including both pharmacologic and nonpharmacologic approaches, and you will receive strategies for handling challenges that arise during treatment. Upon completion of this activity, participants should be better able to: Employ updated ATS/IDSA guidelines to diagnose and manage NTM-LD promptly; Develop individualized treatment regimens encompassing pharmacologic and nonpharmacologic approaches for patients with NTM-LD according to guideline recommendations and patient factors/goals; and Apply team-based strategies to manage medication adverse events, improve treatment adherence, decrease disease burden, and optimize patient outcomes.

Go online to PeerView.com/MNQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a recent live webcast, two experts in NTM-LD who represent pulmonology and infectious disease will offer their perspectives to help you achieve greater insight into the recognition and diagnosis of NTM-LD. You will hear the most up-to-date evidence on the management of NTM-LD, including both pharmacologic and nonpharmacologic approaches, and you will receive strategies for handling challenges that arise during treatment. Upon completion of this activity, participants should be better able to: Employ updated ATS/IDSA guidelines to diagnose and manage NTM-LD promptly; Develop individualized treatment regimens encompassing pharmacologic and nonpharmacologic approaches for patients with NTM-LD according to guideline recommendations and patient factors/goals; and Apply team-based strategies to manage medication adverse events, improve treatment adherence, decrease disease burden, and optimize patient outcomes.